6533b856fe1ef96bd12b248a

RESEARCH PRODUCT

A phase 1b, dose-finding study of ruxolitinib plus panobinostat in patients with myelofibrosis.

Bruno MartinoDaniel B. LipkaThomas KindlerSuddhasatta AcharyyaEibhlin ConneallyVincent RibragFlorence BinlichTracy LiuAlessandro M. VannucchiFrancesco PassamontiFlorian H. HeidelSong MuClaire N. HarrisonAmjad HayatJean-jacques Kiladjian

subject

Cancer ResearchRuxolitinibPathologymedicine.medical_specialtybusiness.industryBone marrow fibrosismedicine.diseasechemistry.chemical_compoundDose findingOncologychemistryPanobinostatCancer researchMedicineIn patientbusinessJanus kinaseMyelofibrosisMyeloproliferative neoplasmmedicine.drug

description

7022^ Background: Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by dysregulation of the Janus kinase (JAK) pathway resulting in bone marrow fibrosis, splenomegaly, and debilitat...

https://doi.org/10.1200/jco.2014.32.15_suppl.7022